S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film

Johnson & Johnson - JNJ Competitors

$152.65
+1.52 (+1.01%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$150.83
$152.76
50-Day Range
$151.05
$173.43
52-Week Range
$150.11
$186.69
Volume
5.70 million shs
Average Volume
8.59 million shs
Market Capitalization
$397.54 billion
P/E Ratio
22.65
Dividend Yield
2.96%
Price Target
$174.73

JNJ vs. LLY, ABBV, MRK, PFE, BMY, NVO, AZN, NVS, ABT, and SNY

Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), and Sanofi (SNY). These companies are all part of the "pharmaceutical preparations" industry.

Johnson & Johnson vs.

Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Eli Lilly and has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$28.54 billion11.19$6.24 billion$6.9048.71
Johnson & Johnson$94.94 billion4.19$17.94 billion$6.7422.65

Eli Lilly and has a net margin of 21.88% compared to Johnson & Johnson's net margin of 18.90%. Eli Lilly and's return on equity of 73.61% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and 21.88% 73.61% 15.06%
Johnson & Johnson 18.90% 35.76% 15.05%

82.1% of Eli Lilly and shares are held by institutional investors. Comparatively, 67.9% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.4% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eli Lilly and received 75 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 71.21% of users gave Eli Lilly and an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Eli Lilly andOutperform Votes
1118
71.21%
Underperform Votes
452
28.79%
Johnson & JohnsonOutperform Votes
1043
65.15%
Underperform Votes
558
34.85%

Eli Lilly and pays an annual dividend of $4.52 per share and has a dividend yield of 1.3%. Johnson & Johnson pays an annual dividend of $4.52 per share and has a dividend yield of 3.0%. Eli Lilly and pays out 65.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 67.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 9 consecutive years and Johnson & Johnson has increased its dividend for 61 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Eli Lilly and currently has a consensus target price of $382.05, suggesting a potential upside of 13.66%. Johnson & Johnson has a consensus target price of $174.73, suggesting a potential upside of 14.47%. Given Johnson & Johnson's higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.46

In the previous week, Eli Lilly and had 8 more articles in the media than Johnson & Johnson. MarketBeat recorded 25 mentions for Eli Lilly and and 17 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.63 beat Eli Lilly and's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and
9 Very Positive mention(s)
7 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Johnson & Johnson
9 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Eli Lilly and beats Johnson & Johnson on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JNJ vs. The Competition

MetricJohnson & JohnsonPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$393.59B$5.50B$4.36B$14.07B
Dividend Yield2.99%2.62%2.32%3.95%
P/E Ratio22.653.5772.1819.15
Price / Sales4.19288.673,467.8510.27
Price / Cash11.6119.4827.6624.19
Price / Book5.204.144.466.40
Net Income$17.94B$186.76M$115.25M$872.59M
7 Day Performance0.18%-1.13%-0.85%0.73%
1 Month Performance-2.13%-8.33%-6.62%-7.18%
1 Year Performance-13.72%-13.91%-16.08%-15.34%

Johnson & Johnson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and
3.0877 of 5 stars
$330.97
0.0%
$382.05
+15.4%
+16.3%$314.52B$28.54B47.9739,000
ABBV
AbbVie
2.6496 of 5 stars
$153.67
-2.0%
$161.12
+4.8%
-2.1%$271.90B$58.05B23.2550,000Options Volume
News Coverage
MRK
Merck & Co., Inc.
3.2309 of 5 stars
$104.40
-1.1%
$119.35
+14.3%
+28.8%$265.03B$59.28B18.2869,000
PFE
Pfizer
3.6962 of 5 stars
$40.01
-1.6%
$50.38
+25.9%
-23.5%$225.83B$100.33B7.3083,000Insider Buying
BMY
Bristol-Myers Squibb
2.8885 of 5 stars
$67.24
-0.4%
$79.69
+18.5%
-7.6%$141.12B$46.16B22.7934,300Positive News
NVO
Novo Nordisk A/S
2.5997 of 5 stars
$146.69
-0.4%
$697.78
+375.7%
+43.4%$331.96B$25.06B42.2755,185
AZN
AstraZeneca
2.4729 of 5 stars
$66.57
-0.6%
$126.00
+89.3%
+4.3%$206.35B$44.35B62.2283,500
NVS
Novartis
1.8012 of 5 stars
$81.96
-2.0%
$82.63
+0.8%
-3.8%$181.34B$50.55B25.85101,703
ABT
Abbott Laboratories
3.3947 of 5 stars
$96.86
-1.5%
$124.67
+28.7%
-17.6%$168.34B$43.65B24.77115,000News Coverage
SNY
Sanofi
2.4218 of 5 stars
$48.79
+0.5%
$102.88
+110.9%
+2.1%$123.03B$45.31B17.2491,573Options Volume
News Coverage
This page (NYSE:JNJ) was last updated on 3/26/2023 by MarketBeat.com Staff